CompletedNot Applicable

Lymphocyte Immunophenotyping in Common Variable Immunodeficiency

United Kingdom210 participantsStarted 2020-09-01

Plain-language summary

The purpose of this study is to discover if differences in the surface markers of B-cells (antibody producing cells of the immune system) in Common Variable Immune Deficiency (CVID) are related to CVID or its complications/treatment (e.g. bronchiectasis, granulomatous disease, immunoglobulin treatment). The study hypothesis is that the altered B-cell surface markers are related to CVID, and not to the complications or treatment of CVID.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 or over * Competent to consent * Have diagnosis of Common Variable Immunodeficiency, granulomatous disease, on long term immunoglobulin or bronchiectasis. Exclusion Criteria: * Under 18 * Unable to consent. * Medical problem that could alter B-cell immunophenotype (except for the diagnoses in the inclusion criteria)/

What they're measuring

Percentage of B-cells of all lymphocytes

Timeframe: 5 months

Percentage of class switched memory B-cells as a percentage of B-cells

Timeframe: 5 months

Trial details

NCT IDNCT01196702

SponsorBarts & The London NHS Trust

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-30

View on ClinicalTrials.gov More Common Variable Immunodeficiency trials